Seo Jung-jin
SJ
Seo Jung-jin
Chairman of Celltrion Group
Rate
About
Seo Jung-jin is the Chairman of Celltrion Group, a South Korean biopharmaceutical company he founded in 1999. He is credited with developing the world's first antibody biosimilar, Remsima. Seo is currently leading Celltrion's strategic shift from a biosimilar manufacturer to a developer of novel drugs. He returned to management in March 2023 after a brief departure.
Frequently asked
Who is Seo Jung-jin?
Seo Jung-jin is the Chairman of Celltrion Group, a South Korean biopharmaceutical company he founded in 1999. He is credited with developing the world's first antibody biosimilar, Remsima. Seo is currently leading Celltrion's strategic shift from a biosimilar manufacturer to a developer of novel drugs. He returned to management in March 2023 after a brief departure.
What is Seo Jung-jin's current role?
Seo Jung-jin is currently Chairman of Celltrion Group.
Comments
No comments yet. Be the first to share your take.
Profile
About Seo Jung-jin
Seo Jung-jin is Chairman of Celltrion Group. This profile tracks their companies, funding activity, and news mentions across the AI ecosystem.